Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Tenofovir 1% vaginal gel
print preview
bookmark
share with colleague
General Information
Company
Gilead Sciences Inc.
Description
1% vaginal gel formulation of tenofovir, a nucleotide analog prodrug reverse transcriptase inhibitor
Molecular Target
HIV reverse transcriptase
Mechanism of Action
HIV reverse transcriptase inhibitor
Latest Stage of Development
Phase II
Indication
HIV / AIDS
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy